Document is current
Any future updates will be listed below
-
Authors
Berro, Lais F.
Cook, Jemma E.
Moreira-Junior, Eliseu C.
Hembree, Heather L.
Comfort, Victoria L. https://orcid.org/0009-0009-7087-4364
Rüedi-Bettschen, Daniela https://orcid.org/0000-0003-2393-6824
Platt, Donna M.
Rowlett, James K. https://orcid.org/0000-0002-4077-5017
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (DA043204)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (DA011792)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (DA058666)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (DA049886)
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (AA029023)
- License Information
-
More Information
Article History
Received: 2 June 2025
Revised: 23 October 2025
Accepted: 7 November 2025
First Online: 21 November 2025
Competing interests
: JKR is founder and director of Impatia Therapeutics, LLC, which was established to provide funding mechanisms for drug development purposes. As of this writing, Impatia Therapeutics, LLC, has no ownership, licensing rights, or financial support associated with the studies presented in this manuscript. The use and data presented in this study are part of a patent: “Methods for treating benzodiazepine misuse/use disorder”; Inventor: James Rowlett; Patent application UMMC Docket No. 19-1003 and published as US Patent Application No. 12,233,070 (Feb 25, 2025). Other authors of this paper declare that they have no competing interests.
